Louis Edward Tamayo

CIK: 0002083206

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (33.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LXEO

Lexeo Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

LXEO
Lexeo Therapeutics, Inc.
Sep 24, 2026
Award(A)
Stock Option (right to buy)
Direct
54.8K shares-
LXEO
Lexeo Therapeutics, Inc.
Aug 18, 2026
Sale(S)
Direct
4.1K shares at avg. $4.91$20K
LXEO
Lexeo Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
4.6K shares at avg. $4.49$21K
LXEO
Lexeo Therapeutics, Inc.
Jun 29, 2026
Award(A)
Direct
12K shares-
LXEO
Lexeo Therapeutics, Inc.
Feb 4, 2026
Award(A)
Direct
44.7K shares-
LXEO
Lexeo Therapeutics, Inc.
Aug 29, 2025
Award(A)
Direct
45K shares-

		Type	Shares	Price		Ownership
Sep 24, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A) Stock Option (right to buy)	54,750	-	-	Direct
Aug 18, 2026	LXEO Lexeo Therapeutics, Inc.	Sale(S)	4,117	$4.91	$20,203	Direct
Jul 1, 2026	LXEO Lexeo Therapeutics, Inc.	Sale(S)	4,641	$4.49	$20,838	Direct
Jun 29, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	12,000	-	$0	Direct
Feb 4, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A)	44,665	-	$0	Direct
Aug 29, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A)	45,000	-	-	Direct

1-6 of 6 transactions

About Tamayo Louis Edward

Tamayo Louis Edward (SEC CIK 0002083206) files insider reports with the SEC as Chief Financial Officer of Lexeo Therapeutics, Inc. (LXEO).

Signal8 holds 6 ownership filings by Tamayo Louis Edward (1 Form 3, 5 Form 4), filed between Aug 27, 2025 and Sep 28, 2026. Those filings report 6 transactions, from Aug 29, 2025 to Sep 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Tamayo Louis Edward's filings is in NEW YORK, NY.

Recent filings by Tamayo Louis Edward

Sep 24, 2026: Grant or award of LXEO derivative securities (Form 4, code A).
Aug 18, 2026: Open-market sale of LXEO shares (Form 4, code S).
Jul 1, 2026: Open-market sale of LXEO shares (Form 4, code S).
Jun 29, 2026: Grant or award of LXEO shares (Form 4, code A).
Feb 4, 2026: Grant or award of LXEO shares (Form 4, code A).

Other insiders filing for Lexeo Therapeutics, Inc. (LXEO)

Bhalla Narinder Pal, Chief Medical Officer
Otero Jose Manuel, Chief Operating Officer
Townsend Richard Nolan, Chief Executive Officer
Altschuler Steven, Director
Agger Mette Kirstine, Director
COOPERSTONE BRENDA, Director

How to read Form 4 transaction codes